In people with fatty liver disease, those with clearly underactive thyroid (TSH > 4.5 mIU/L) do not have a higher risk of advanced liver scarring once other factors like obesity and diabetes are accounted for, unlike those with mildly elevated TSH (2.5–4.5 mIU/L).
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis would determine whether the dissociation between SCH and fibrosis (vs. low-normal TSH) is reproducible across studies using consistent definitions.
Systematic review and meta-analysis of studies comparing odds of advanced fibrosis in MAFLD patients with SCH (TSH > 4.5) versus low-normal TSH (2.5–4.5) versus strict-normal TSH (<2.5), adjusting for BMI, diabetes, and hypertension.
An RCT would test whether treating SCH in MAFLD patients reduces fibrosis, to determine if the lack of association reflects true biological irrelevance.
Double-blind RCT of 200 MAFLD patients with SCH (TSH > 4.5, FT4 normal) randomized to levothyroxine (target TSH 1.5–2.5) vs. placebo for 3 years, with primary outcome change in MRE-measured liver stiffness.
A prospective cohort would determine whether SCH predicts fibrosis progression independently of low-normal TSH over time.
Prospective cohort of 3,000 MAFLD patients with baseline TSH stratified into <2.5, 2.5–4.5, >4.5 mIU/L, followed for 5 years with annual FIB-4/NFS, analyzing whether SCH independently predicts progression after adjusting for low-normal TSH.
A case-control study would compare prevalence of SCH between MAFLD patients with and without advanced fibrosis, controlling for low-normal TSH.
Case-control study of 600 MAFLD patients: 300 with biopsy-proven F3-F4 fibrosis and 300 with F0-F1, matched for age, sex, BMI, diabetes, and TSH category, comparing prevalence of SCH (TSH > 4.5) between groups.
A cross-sectional study can only show whether SCH and fibrosis coexist at a single time point, as done in this study.
Cross-sectional analysis of 10,000 MAFLD patients with TSH and FIB-4/NFS measured simultaneously, comparing prevalence of advanced fibrosis across TSH categories.